Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing.
about
Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndromeTassDB: a database of alternative tandem splice sitesNanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophyProgress toward therapy with antisense-mediated splicing modulationManipulation of alternative splicing by a newly developed inhibitor of ClksDoxycycline-controlled splicing modulation by regulated antisense U7 snRNA expression cassettesRNA and diseaseLibraries enriched for alternatively spliced exons reveal splicing patterns in melanocytes and melanomas.Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB.Alternative splicing: an important mechanism for myometrial gene regulation that can be manipulated to target specific genes associated with preterm labour.Dynamics of co-transcriptional pre-mRNA folding influences the induction of dystrophin exon skipping by antisense oligonucleotides.Future alternative therapies for β-thalassemia.Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterationsHuR controls mitochondrial morphology through the regulation of BclxL translation.Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron.Antisense oligodeoxynucleotide inhibition as an alternative and convenient method for gene function analysis in pollen tubesStrategies Toward Well-Defined Polymer Nanoparticles Inspired by Nature: Chemistry versus Versatility.Use of fully modified 2'-O-methyl antisense oligos for loss-of-function studies in vertebrate embryos.Effect of Steric Constraint at the γ-Backbone Position on the Conformations and Hybridization Properties of PNAsAntisense oligonucleotide induction of progerin in human myogenic cellsTargeted genetic repair: an emerging approach to genetic therapy.Epigenetic manipulation of gene expression: a toolkit for cell biologistsTuning of alternative splicing--switch from proto-oncogene to tumor suppressorDefective splicing, disease and therapy: searching for master checkpoints in exon definition.Development of novel bioanalytical methods to determine the effective concentrations of phosphorodiamidate morpholino oligomers in tissues and cells.The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides.Alternative splicing: functional diversity among voltage-gated calcium channels and behavioral consequences.Direct intraventricular delivery of drugs to the rodent central nervous system.Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo.Effective delivery of antisense peptide nucleic acid oligomers into cells by anthrax protective antigenFunctional characterization of alternatively spliced human SECISBP2 transcript variants.RNA repair restores hemoglobin expression in IVS2-654 thalassemic mice.Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides.Alternative splicing and tumor progression.Alternative splicing and disease.Antisense makes sense in engineered regenerative medicine.Peptide-mediated cellular delivery of oligonucleotide-based therapeutics in vitro: quantitative evaluation of overall efficacy employing easy to handle reporter systems.Polypyrimidine tract binding protein prevents activity of an intronic regulatory element that promotes usage of a composite 3'-terminal exon.Targeting the splicing of mRNA in autoimmune diseases: BAFF inhibition in Sjögren's syndrome as a proof of conceptThe role of carrier size in the pharmacodynamics of antisense and siRNA oligonucleotides.
P2860
Q24539118-24C9C239-9C8C-40AD-9938-42D5DC9A8767Q24675725-618BB8EB-8EBE-43B2-A970-6195B964C1BFQ26992271-A6DFE09F-4356-4804-B88F-D0B0382CE766Q27489807-FD498343-410F-4E8D-A917-26FB8E9EAD38Q28249376-0FA90284-8187-4D0E-8852-327BEFD96434Q28290763-CF2B8E41-F7E6-4D98-8326-92A444210556Q29615183-CDE441CA-1E8D-4C46-AC1D-4459D334E09DQ30780305-39F7D530-D290-4BFC-8880-D33B17D66CADQ33269609-090CDBE7-2F03-4083-AD71-8A34149CBD83Q33287749-E3A7D890-0B04-42B5-9562-2453C90B2257Q33325470-FE7E036D-78A8-44D3-8D7B-515F70A41AE8Q33659678-C2A194BF-C7AF-41EB-B1D2-B70745CDF494Q34068205-0C1250BE-A9AF-410F-9950-DF56AADF2CD9Q34349781-9AAE5C1C-A460-46C7-8115-D2BB42D15DB5Q34353625-1B19EA4E-226D-4164-82CB-7D2420DE7461Q34634669-08716BE3-8BE9-4EA8-82B2-339301889E7BQ34845562-0B9ACAEA-344F-472C-ADDB-15DDD21B098DQ35064569-1EAB1DB5-92F8-42D0-AF4D-2833EA0ADB4BQ35110193-FA78C5B8-3ECD-463F-9F10-886C4FC57C67Q35180565-1BA299EC-99AE-4C56-B4D4-1CF8C67711F8Q35190980-069C8809-EEA2-4398-89AF-5B4E6DA95727Q36169056-C97A7920-D754-4B72-B9C8-4CFDEB392538Q36503982-FEFC279C-3D53-4660-BB8A-5096DEA42FF2Q36541361-1AABFF12-A439-4E62-B92E-8B5783549CBAQ36602932-290D4E39-DF4E-414A-89EF-22D01573C195Q36740806-C719F1E9-DC3A-46EF-92CC-DE84029B2023Q36763193-1FEF15D2-54E3-42F8-A59D-3DB642DC8021Q36921774-892892BE-9A33-40A1-9CE8-2A7F4045C91DQ36924803-35265D66-D803-4FD4-AFF6-861560E7D413Q36968203-2D4340C9-16EF-426D-814D-7408505502C6Q37014732-837152E8-E347-4921-9EAF-4A8B99DD1D99Q37079038-D8574C24-7499-4084-B96E-BD49DAF0A1A2Q37193000-1CA0467E-2AE1-4F77-854F-1B927D58DE4FQ37222930-6BF9875A-E063-4BC4-96E5-A058ACFFB661Q37320845-BC6ED88F-2CC2-434A-8542-21EDA33BCF97Q37328072-946754C4-5132-499C-9807-7CB76CA40836Q37347451-D87C04F9-A285-4A6B-9C57-E79A1BB879B9Q37431966-DEB1EA80-D4D5-4949-99EF-90F093AE386FQ37696041-C657A6EA-0284-4F61-8460-62BB65D29C2AQ37724167-14DE1C9F-56D5-4766-9AB6-BF9787C372D0
P2860
Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Therapeutic potential of antis ...... ators of alternative splicing.
@ast
Therapeutic potential of antis ...... ators of alternative splicing.
@en
type
label
Therapeutic potential of antis ...... ators of alternative splicing.
@ast
Therapeutic potential of antis ...... ators of alternative splicing.
@en
prefLabel
Therapeutic potential of antis ...... ators of alternative splicing.
@ast
Therapeutic potential of antis ...... ators of alternative splicing.
@en
P2860
P356
P1476
Therapeutic potential of antis ...... ators of alternative splicing.
@en
P2093
Peter Sazani
P2860
P304
P356
10.1172/JCI200319547
P407
P50
P577
2003-08-01T00:00:00Z